• Bortezomib (PS-341): Applied Strategies for Reliable Prot...

  2026-03-19

  This authoritative guide addresses key experimental challenges faced by biomedical researchers using Bortezomib (PS-341) (SKU A2614) for apoptosis and cytotoxicity assays. Through real-world scenarios, it demonstrates how APExBIO's Bortezomib ensures reproducible, high-sensitivity results across diverse cancer models, with data-backed insights into assay design, protocol optimization, and vendor reliability. Discover when and why SKU A2614 stands out as the gold standard for proteasome-regulated cellular process investigations.

• ONX-0914 (PR-957): Selective LMP7 Inhibitor for Immunopro...

  2026-03-19

  ONX-0914 (PR-957) is a selective immunoproteasome inhibitor targeting the LMP7 subunit, widely used in autoimmune and inflammatory disease research. It enables precise blockade of proinflammatory cytokine production and supports robust disease modeling with reproducible, dose-dependent effects.

• Epoxomicin: Selective 20S Proteasome Inhibitor for Ubiqui...

  2026-03-18

  Epoxomicin is a highly selective, irreversible 20S proteasome inhibitor prized for its potency in ubiquitin-proteasome pathway research. Its unique α',β'-epoxyketone moiety enables covalent inhibition of chymotrypsin-like activity (IC50 = 4 nM), supporting reproducible protein degradation assays and disease modeling.

• MG-132 Proteasome Inhibitor: Molecular Mechanisms and App...

  2026-03-18

  MG-132 (Z-LLL-al) is a potent, cell-permeable proteasome inhibitor peptide aldehyde widely used in apoptosis assay and cancer research. This article details MG-132's mechanism of action, quantitative inhibitory benchmarks, and integration into cell cycle arrest and oxidative stress workflows. Comprehensive evidence supports its role as a reference compound for ubiquitin-proteasome system inhibition.

• MLN2238: Novel Insights into Proteasome Inhibition and St...

  2026-03-17

  Explore the advanced mechanisms of MLN2238, a potent proteasome β5 subunit inhibitor, with a unique focus on stress-responsive signaling and proteostasis in multiple myeloma research. This article uncovers scientific connections not addressed in existing guides.

• PYR-41 and E1 Enzyme Inhibition: New Frontiers in Ubiquit...

  2026-03-17

  Explore the multifaceted role of PYR-41, a selective ubiquitin-activating enzyme inhibitor, in dissecting ubiquitin signaling, NF-κB pathway modulation, and translational research. This article uniquely integrates recent mechanistic insights and advanced applications for protein degradation and cancer therapeutics development.

• ONX-0914 (PR-957): Advanced Immunoproteasome Inhibition f...

  2026-03-16

  Explore how ONX-0914, a selective immunoproteasome inhibitor, enables advanced mechanistic studies in autoimmune and inflammatory disease models. This article reveals novel insights into LMP7 targeting, cytokine modulation, and caspase-independent cell death—distinct from standard assay guides.

• MLN2238: Reversible 20S Proteasome Inhibitor in Hematolog...

  2026-03-16

  MLN2238 stands out as a next-generation, reversible 20S proteasome β5 subunit inhibitor, enabling robust studies of apoptosis, NF-κB pathway suppression, and proteasome inhibitor resistance in multiple myeloma and lymphoma research. Its high potency, unique mechanistic insight into ROS/JNK/CREB signaling, and proven efficacy in bortezomib-resistant models provide researchers with a powerful tool for dissecting proteotoxic stress and advancing translational breakthroughs.

• Carfilzomib (PR-171): Redefining Proteasome Inhibition in...

  2026-03-15

  Explore how Carfilzomib (PR-171), a potent irreversible proteasome inhibitor, uniquely modulates multi-modal cell death and tumor suppression in cancer biology. This article delves deeper into ER stress-mediated mechanisms and translational applications, offering novel insights beyond standard protocols.

• MLN2238: Advanced Insights into Proteasome Inhibition and...

  2026-03-14

  Discover the unique mechanisms of MLN2238, a potent reversible 20S proteasome inhibitor, and its impact on multiple myeloma research, lymphoma models, and bortezomib-resistant cancer cell lines. This article delivers novel perspectives on CREB signaling, apoptosis induction, and translational applications beyond conventional paradigms.

• Bortezomib (PS-341): Practical Answers for Cell-Based Ass...

  2026-03-13

  This article offers scenario-driven, evidence-based guidance for using Bortezomib (PS-341) (SKU A2614) in cell viability and apoptosis assays. Drawing on peer-reviewed data and firsthand lab perspectives, it addresses experimental design, optimization, and product reliability to help researchers leverage this reversible 20S proteasome inhibitor for reproducible, high-impact results.

• Disulfiram in Cancer Proteasome Research: Mechanisms, Inn...

  2026-03-13

  Explore the unique mechanisms of Disulfiram as a dopamine β-hydroxylase inhibitor and proteasome modulator in cancer research. This article offers an advanced perspective on Disulfiram’s copper complexes, apoptotic cell death induction, and translational workflow, distinct from existing coverage.

• Carfilzomib (PR-171): Next-Generation Proteasome Inhibiti...

  2026-03-12

  Explore how Carfilzomib (PR-171), a potent irreversible proteasome inhibitor, is reshaping cancer biology through multi-modal cell death and advanced radiosensitization. This article offers a deep dive into recent mechanistic discoveries, unique application strategies, and future research pathways.

• MLN2238: A Next-Generation Reversible 20S Proteasome β5 S...

  2026-03-12

  MLN2238 is a potent, selective, and reversible inhibitor of the proteasome β5 subunit, offering nanomolar potency and broad utility for multiple myeloma and lymphoma research. This article provides atomic, verifiable facts on MLN2238’s mechanism, evidence base, and workflow integration, positioning it as a leading tool for studies involving chymotrypsin-like proteasome inhibition and bortezomib-resistant cancer models.

• Topotecan HCl: Mechanisms and Benchmarks as a Topoisomera...

  2026-03-11

  Topotecan HCl, a semisynthetic camptothecin analogue, is a potent topoisomerase 1 inhibitor used in cancer research. It exerts antitumor activity by stabilizing the topoisomerase I-DNA complex, inducing DNA damage and apoptosis in proliferating tumor cells. This article details its mechanism, efficacy benchmarks, workflow integration, and common misconceptions.

16712 records 1/1115 page Next 12345 下5页 Last page